The Alliance for Regenerative Medicine (ARM) today announced its eighth annual Advanced Therapies Summit, to be held March 14, 2018 in Amsterdam, the Netherlands. This one-day meeting is the region’s premier collaborative forum for the Advanced Therapies Medicinal Products (ATMP) sector, bringing together experts in regulatory strategy, health technology assessment, commercialization and industrialization issues, as well as executives from Europe’s leading cell and gene therapy developers to exchange views and make recommendations on how best to advance the ATMP sector in Europe.
The Advanced Therapies Summit will highlight major recent achievements across the sector and explore the main challenges experienced along the path from discovery to delivery of transformative and potentially curative therapies. This year’s program will feature interactive discussions and networking opportunities with policy makers leading the evolution of the ATMP framework in Europe and executives from leading companies in the ATMP sector.
“The Advanced Therapies Summit is a timely and important opportunity for the sector’s European stakeholders to engage in meaningful discussion at this critical point in the field’s development,” said Janet Lambert, ARM CEO. “With the many opportunities and challenges facing us today, this exchange of ideas is vital to our sector’s advancement and success.”
A detailed agenda will be released in the coming weeks. Session topics will include:
Sponsors for the 2018 Advanced Therapies Summit include Lonza, PCT Cell Therapy and TiGenix.
Registration is now open – to learn more and to secure a spot, please visit ARM’s event page or contact Chelsey Hathaway, firstname.lastname@example.org. For members of the media interested in attending, please contact Lyndsey Scull (email@example.com) for information regarding complimentary press registration.
The event will be held at the Hilton Amsterdam, Apollolaan 138, 1077 BG Amsterdam, The Netherlands.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 270 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.